Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway
- PMID: 23968914
- DOI: 10.1016/j.biocel.2013.08.002
Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway
Abstract
The metastasis suppressor CD82/KAI-1, which is a member of the tetraspanin superfamily, has been proposed to exert its activity together with glycosphingolipids. However, the mechanism of CD82 inhibition has not been fully elucidated. The present study aimed to investigate the synergistic inhibition of cell migration by the tetraspanin CD82 and gangliosides and to correlate this inhibition with activation of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR/cMet) in Hepa1-6 cell lines, whose motility and migration is stimulated by epidermal growth factor (EGF) and hepatocyte growth factor (HGF) in vitro. We found that Hepa1-6 cells transfected with the CD82 gene exhibited decreased migration in response to EGF and HGF. EGF-stimulated phosphorylation of EGFR at Tyr1173 was inhibited in these cells, which contributed to the attenuation of EGFR. Ectopic expression of CD82 in Hepa1-6 cells inhibited HGF-stimulated tyrosine phosphorylation of cMet at Tyr1313 and Tyr1365 without affecting the expression of cMet. These inhibitory effects were enhanced when CD82 was introduced with Ganglioside GM3 alone or GM2/GM3. Reduction of CD82 expression by RNA interference together with depletion of glycosphingolipids with P4 significantly enhanced cell motility and increased the expression of EGFR and its phosphorylation at Tyr1173 in response to EGF. Increased cell motility and HGF-dependent activation of cMet at Tyr1313 and Tyr1365 resulted from decreased CD82 levels and increased GM3. Furthermore, CD82 expression selectively attenuated EGFR and cMet signalling via phosphatidylinositol 3-kinase/Akt but had no affect on the activity of the MAPK signalling pathway. These results suggest that the synergistic effects of CD82 and GM3 or GM2/GM3 on EGFR expression and phosphorylation and cMet activation are responsible for CD82 inhibition of EGF- and HGF-dependent cell motility and migration of Hepa1-6 cells.
Keywords: Akt; CD82/KAI-1; EGFR; GM3; HGFR; Metastasis.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Ganglioside GM3 promotes HGF-stimulated motility of murine hepatoma cell through enhanced phosphorylation of cMet at specific tyrosine sites and PI3K/Akt-mediated migration signaling.Mol Cell Biochem. 2013 Oct;382(1-2):83-92. doi: 10.1007/s11010-013-1720-9. Epub 2013 Jun 8. Mol Cell Biochem. 2013. PMID: 23749170
-
Gangliosides and CD82 inhibit the motility of colon cancer by downregulating the phosphorylation of EGFR at different tyrosine sites and signaling pathways.Mol Med Rep. 2020 Nov;22(5):3994-4002. doi: 10.3892/mmr.2020.11467. Epub 2020 Aug 27. Mol Med Rep. 2020. PMID: 33000220
-
Ganglioside GM3 exerts opposite effects on motility via epidermal growth factor receptor and hepatocyte growth factor receptor-mediated migration signaling.Mol Med Rep. 2015 Apr;11(4):2959-66. doi: 10.3892/mmr.2014.3087. Epub 2014 Dec 12. Mol Med Rep. 2015. PMID: 25503644
-
Carbohydrate to carbohydrate interaction in development process and cancer progression.Glycoconj J. 2012 Dec;29(8-9):627-37. doi: 10.1007/s10719-012-9380-7. Epub 2012 May 18. Glycoconj J. 2012. PMID: 22610315 Review.
-
GM3 and cancer.Glycoconj J. 2015 Feb;32(1-2):1-8. doi: 10.1007/s10719-014-9572-4. Epub 2015 Jan 23. Glycoconj J. 2015. PMID: 25613425 Review.
Cited by
-
How Do Gangliosides Regulate RTKs Signaling?Cells. 2013 Dec 6;2(4):751-67. doi: 10.3390/cells2040751. Cells. 2013. PMID: 24709879 Free PMC article.
-
Role of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and Cancer.Cells. 2016 Nov 29;5(4):43. doi: 10.3390/cells5040043. Cells. 2016. PMID: 27916834 Free PMC article. Review.
-
Metabolomics of Esophageal Squamous Cell Carcinoma Tissues: Potential Biomarkers for Diagnosis and Promising Targets for Therapy.Biomed Res Int. 2022 Jun 23;2022:7819235. doi: 10.1155/2022/7819235. eCollection 2022. Biomed Res Int. 2022. PMID: 35782075 Free PMC article.
-
Exploiting receptor tyrosine kinase co-activation for cancer therapy.Drug Discov Today. 2017 Jan;22(1):72-84. doi: 10.1016/j.drudis.2016.07.010. Epub 2016 Jul 21. Drug Discov Today. 2017. PMID: 27452454 Free PMC article. Review.
-
Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling.Front Cell Dev Biol. 2019 May 3;7:70. doi: 10.3389/fcell.2019.00070. eCollection 2019. Front Cell Dev Biol. 2019. PMID: 31131274 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous